Lifeward 향후 성장
Future 기준 점검 2/6
Lifeward은 연간 수입과 매출이 각각 51.7%와 38.6% 증가할 것으로 예상되고 EPS는 연간 69.3%만큼 증가할 것으로 예상됩니다.
핵심 정보
51.7%
이익 성장률
69.33%
EPS 성장률
| Medical Equipment 이익 성장 | 16.4% |
| 매출 성장률 | 38.6% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 26 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Jun 18
LFWD: Long Term Safety Data Will Support Stock Upside Potential
Analysts have modestly adjusted their price target on Lifeward, keeping fair value steady at $20.00. They fine tuned assumptions around the discount rate, profit margin, and future P/E to reflect updated valuation work, without a clear directional shift in the overall outlook.내러티브 업데이트 • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.내러티브 업데이트 • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
내러티브 업데이트 • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
내러티브 업데이트 • Apr 15
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.내러티브 업데이트 • Mar 31
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.내러티브 업데이트 • Mar 17
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).내러티브 업데이트 • Mar 03
LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.내러티브 업데이트 • Feb 17
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).내러티브 업데이트 • Feb 03
LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).내러티브 업데이트 • Jan 20
LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).내러티브 업데이트 • Jan 06
LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.내러티브 업데이트 • Dec 17
LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.내러티브 업데이트 • Dec 03
LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.내러티브 업데이트 • Nov 19
LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.분석 기사 • Sep 25
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...내러티브 업데이트 • Aug 16
FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.분석 기사 • Jun 19
Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...새로운 내러티브 • May 11
AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.분석 기사 • Feb 05
Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Oct 30
Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...분석 기사 • Oct 15
Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Aug 01
ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...분석 기사 • May 30
Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 78 | -11 | N/A | N/A | 2 |
| 12/31/2027 | 51 | -14 | N/A | N/A | 2 |
| 12/31/2026 | 28 | -24 | N/A | N/A | 2 |
| 3/31/2026 | 21 | -26 | -15 | -15 | N/A |
| 12/31/2025 | 22 | -20 | -17 | -17 | N/A |
| 9/30/2025 | 24 | -30 | -17 | -17 | N/A |
| 6/30/2025 | 24 | -30 | -18 | -18 | N/A |
| 3/31/2025 | 25 | -27 | -20 | -20 | N/A |
| 12/31/2024 | 26 | -29 | -22 | -22 | N/A |
| 9/30/2024 | 25 | -19 | -22 | -22 | N/A |
| 6/30/2024 | 23 | -24 | -25 | -25 | N/A |
| 3/31/2024 | 18 | -24 | -23 | -23 | N/A |
| 12/31/2023 | 14 | -22 | -21 | -21 | N/A |
| 9/30/2023 | 9 | -22 | -20 | -20 | N/A |
| 6/30/2023 | 6 | -20 | -17 | -17 | N/A |
| 3/31/2023 | 6 | -20 | -17 | -17 | N/A |
| 12/31/2022 | 6 | -20 | -18 | -18 | N/A |
| 9/30/2022 | 5 | -18 | -17 | -17 | N/A |
| 6/30/2022 | 6 | -15 | -15 | -15 | N/A |
| 3/31/2022 | 6 | -14 | -14 | -14 | N/A |
| 12/31/2021 | 6 | -13 | -12 | -11 | N/A |
| 9/30/2021 | 6 | -12 | -11 | -11 | N/A |
| 6/30/2021 | 5 | -12 | -11 | -11 | N/A |
| 3/31/2021 | 5 | -12 | -11 | -11 | N/A |
| 12/31/2020 | 4 | -13 | -13 | -13 | N/A |
| 9/30/2020 | 4 | -14 | -14 | -14 | N/A |
| 6/30/2020 | 5 | -14 | -14 | -14 | N/A |
| 3/31/2020 | 4 | -15 | -15 | -15 | N/A |
| 12/31/2019 | 5 | -16 | N/A | -15 | N/A |
| 9/30/2019 | 5 | -17 | N/A | -14 | N/A |
| 6/30/2019 | 6 | -18 | N/A | -14 | N/A |
| 3/31/2019 | 7 | -19 | N/A | -14 | N/A |
| 12/31/2018 | 7 | -22 | N/A | -15 | N/A |
| 9/30/2018 | 6 | -23 | N/A | -18 | N/A |
| 6/30/2018 | 7 | -24 | N/A | -20 | N/A |
| 3/31/2018 | 7 | -25 | N/A | -21 | N/A |
| 12/31/2017 | 8 | -25 | N/A | -22 | N/A |
| 9/30/2017 | 8 | -27 | N/A | -24 | N/A |
| 6/30/2017 | 7 | -29 | N/A | -25 | N/A |
| 3/31/2017 | 6 | -32 | N/A | -27 | N/A |
| 12/31/2016 | 6 | -33 | N/A | -27 | N/A |
| 9/30/2016 | 6 | -31 | N/A | -27 | N/A |
| 6/30/2016 | 5 | -30 | N/A | -27 | N/A |
| 3/31/2016 | 5 | -27 | N/A | -26 | N/A |
| 12/31/2015 | 4 | -25 | N/A | -25 | N/A |
| 9/30/2015 | 4 | -23 | N/A | -21 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: LFWD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: LFWD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: LFWD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: LFWD 의 수익(연간 38.6%)이 US 시장(연간 13%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: LFWD 의 수익(연간 38.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: LFWD의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/13 04:17 |
| 종가 | 2026/07/10 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Lifeward Ltd.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |